Here are my top 3 presentations (specifically for breast medical oncology) that I would say are most impactful (now or soon), with slides attached. GS3-04 - Capivasertib Phase III (CAPItello-291) Trial – these results will likely change standards for post CDKi progression for HR+/HE...

POSITIVE – appears that for women at least 18 months into endocrine therapy, stopping ET for up to 2 years in an attempt to have children doesn’t result in significantly worse outcomes. Very big clinical question that has been unanswered for some time. DB-03/DB-02 – firmly estab...

CAPItello-291  was one. First phase III trial showing benefit of adding AKT inhibitor to endocrine therapy. Maybe some toxicity concerns but this combination may become SOC in second line setting. EMERALD: new oral SERD with improved outcomes in ER+ HER2- MBC especially in ESR1 tumors. POSI...

It is hard to choose the top 3 but I was intrigued by the following: MonarchE update - 4-year iDFS survival benefit with addition of 2 years of abemacicilib to adjuvant endocrine therapy in high risk, HR+/HER2- breast cancer. EMERALD trial, especially the superiority of elacestrant over fulves...

Here are my top 3: POSITIVE: Found that holding endocrine therapy to try to conceive did not impact the risk of recurrence with short term f/u (41 months). Important data for young women with ER+ breast cancer who desire children. DESTINY-Breast03: Updated analysis now has OS benefit (HR 0.64) and...